<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782117</url>
  </required_header>
  <id_info>
    <org_study_id>C-AM-1C AND C-AM-1D</org_study_id>
    <nct_id>NCT02782117</nct_id>
  </id_info>
  <brief_title>Luminopia One Pilot Study</brief_title>
  <official_title>Luminopia One Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luminopia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luminopia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm, multi-center, open-label pilot study to evaluate the feasibility, safety, and
      efficacy of the Luminopia One digital therapeutic in improving visual acuity in a pediatric
      amblyopia population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">February 6, 2019</completion_date>
  <primary_completion_date type="Actual">February 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single-arm, multi-center, open-label pilot study conducted in two phases. Phase 1 enrolled 10 participants at 1 site and phase 2 enrolled 74 participants at 9 sites.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amblyopic eye best-corrected visual acuity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Electronic ATS-HOTV protocol for participants &lt; 7 years of age and electronic ETDRS protocol for participants ≥ 7 years of age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amblyopic eye best-corrected visual acuity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Electronic ATS-HOTV protocol for participants &lt; 7 years of age and electronic ETDRS protocol for participants ≥ 7 years of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopic eye best-corrected visual acuity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Electronic ATS-HOTV protocol for participants &lt; 7 years of age and electronic ETDRS protocol for participants ≥ 7 years of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Duration spent using the device divided by duration of treatment prescribed (objectively monitored)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>Treatment Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Regimen A will use the Luminopia device for an hour per day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Luminopia One</intervention_name>
    <description>Luminopia One is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.</description>
    <arm_group_label>Treatment Regimen A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Eligibility Criteria:

          -  Age 4 to &lt;8 years (phase 1) or age 4 to &lt;13 years (phase 2)

          -  Monocular amblyopia associated with anisometropia, strabismus or both combined

          -  Amblyopic eye best-corrected visual acuity (BCVA) 20/40 to 20/200 inclusive (0.3-1.0
             logMAR)

          -  Fellow eye BCVA 20/25 or better (phase 1) or 20/32 or better (phase 2)

          -  Interocular BCVA difference ≥3 lines (≥0.3 logMAR)

          -  Visual acuity stability in current refractive correction (phase 2)

          -  Corrected distance heterotropia ≤5 prism diopters on simultaneous prism and cover test
             (SPCT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hunter, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Physicians of Central Florida</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wheaton Eye Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kids Eye Care of Maryland</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Eye Care of Michigan</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Eye Center</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conestoga Eye</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Pediatric Eye Center</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <disposition_first_submitted>February 20, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>February 20, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 25, 2020</disposition_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

